180 related articles for article (PubMed ID: 15805294)
1. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A
Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294
[TBL] [Abstract][Full Text] [Related]
2. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression.
Baron F; Turhan AG; Giron-Michel J; Azzarone B; Bentires-Alj M; Bours V; Bourhis JH; Chouaib S; Caignard A
Blood; 2002 Mar; 99(6):2107-13. PubMed ID: 11877286
[TBL] [Abstract][Full Text] [Related]
3. The decreased susceptibility of Bcr/Abl targets to NK cell-mediated lysis in response to imatinib mesylate involves modulation of NKG2D ligands, GM1 expression, and synapse formation.
Cebo C; Da Rocha S; Wittnebel S; Turhan AG; Abdelali J; Caillat-Zucman S; Bourhis JH; Chouaib S; Caignard A
J Immunol; 2006 Jan; 176(2):864-72. PubMed ID: 16393970
[TBL] [Abstract][Full Text] [Related]
4. BCR/ABL promotes dendritic cell-mediated natural killer cell activation.
Terme M; Borg C; Guilhot F; Masurier C; Flament C; Wagner EF; Caillat-Zucman S; Bernheim A; Turhan AG; Caignard A; Zitvogel L
Cancer Res; 2005 Jul; 65(14):6409-17. PubMed ID: 16024645
[TBL] [Abstract][Full Text] [Related]
5. p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.
Geay JF; Buet D; Zhang Y; Foudi A; Jarrier P; Berthebaud M; Turhan AG; Vainchenker W; Louache F
Cancer Res; 2005 Apr; 65(7):2676-83. PubMed ID: 15805265
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility to natural killer cell-mediated cytolysis is independent of the level of target cell class I HLA expression.
Leiden JM; Karpinski BA; Gottschalk L; Kornbluth J
J Immunol; 1989 Mar; 142(6):2140-7. PubMed ID: 2493507
[TBL] [Abstract][Full Text] [Related]
7. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
Wang Z; Sampath J; Fukuda S; Pelus LM
Cancer Res; 2005 Sep; 65(18):8224-32. PubMed ID: 16166298
[TBL] [Abstract][Full Text] [Related]
9. Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Volpe G; Cignetti A; Panuzzo C; Kuka M; Vitaggio K; Brancaccio M; Perrone G; Rinaldi M; Prato G; Fava M; Geuna M; Pautasso M; Casnici C; Signori E; Tonon G; Tarone G; Marelli O; Fazio VM; Saglio G
Cancer Res; 2007 Jun; 67(11):5300-7. PubMed ID: 17545610
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of the TGFbeta signalling pathway by Bcr-Abl: implications for haemopoietic cell growth and chronic myeloid leukaemia.
Møller GM; Frost V; Melo JV; Chantry A
FEBS Lett; 2007 Apr; 581(7):1329-34. PubMed ID: 17349636
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
12. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia.
Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV
Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL activity is critical for the immunogenicity of chronic myelogenous leukemia cells.
Brauer KM; Werth D; von Schwarzenberg K; Bringmann A; Kanz L; Grünebach F; Brossart P
Cancer Res; 2007 Jun; 67(11):5489-97. PubMed ID: 17545631
[TBL] [Abstract][Full Text] [Related]
14. MHC class I expression on tumor targets inhibits natural killer cell-mediated cytotoxicity without interfering with target recognition.
Kaufman DS; Schoon RA; Leibson PJ
J Immunol; 1993 Feb; 150(4):1429-36. PubMed ID: 8432986
[TBL] [Abstract][Full Text] [Related]
15. Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells.
Zhang C; Zhang J; Sun R; Feng J; Wei H; Tian Z
Int Immunopharmacol; 2005 Jun; 5(6):1057-67. PubMed ID: 15829421
[TBL] [Abstract][Full Text] [Related]
16. [Influence of HLA class I molecules expression on tumor cell resistance to NK lysis and the IFN-gamma regulatory effect].
Zhang C; Tian Z; Hou G
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):369-72. PubMed ID: 11810763
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma upregulates the susceptibility of human neuroblastoma cells to interleukin-2-activated natural killer cells.
Handgretinger R; Kimmig A; Lang P; Daurer B; Kuci S; Bruchelt G; Treuner J; Niethammer D
Nat Immun Cell Growth Regul; 1989; 8(4):189-96. PubMed ID: 2507905
[TBL] [Abstract][Full Text] [Related]
18. The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4+ and CD8+ T lymphocytes.
Wagner WM; Ouyang Q; Pawelec G
Cancer Immunol Immunother; 2003 Feb; 52(2):89-96. PubMed ID: 12594572
[TBL] [Abstract][Full Text] [Related]
19. BCR-ABL is not an immunodominant antigen in chronic myelogenous leukemia.
Grünebach F; Mirakaj V; Mirakaj V; Müller MR; Brümmendorf T; Brossart P
Cancer Res; 2006 Jun; 66(11):5892-900. PubMed ID: 16740729
[TBL] [Abstract][Full Text] [Related]
20. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
Roger R; Issaad C; Pallardy M; Léglise MC; Turhan AG; Bertoglio J; Bréard J
Blood; 1996 Feb; 87(3):1113-22. PubMed ID: 8562937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]